AT516818T - Auristatin conjugates and their use for the treatment of cancer, autoimmunk range, or infectious disease - Google Patents

Auristatin conjugates and their use for the treatment of cancer, autoimmunk range, or infectious disease

Info

Publication number
AT516818T
AT516818T AT03772186T AT03772186T AT516818T AT 516818 T AT516818 T AT 516818T AT 03772186 T AT03772186 T AT 03772186T AT 03772186 T AT03772186 T AT 03772186T AT 516818 T AT516818 T AT 516818T
Authority
AT
Austria
Prior art keywords
autoimmunk
cancer
treatment
range
use
Prior art date
Application number
AT03772186T
Other languages
German (de)
Inventor
Peter Senter
Svetlana Doronina
Brian Toki
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US40040302P priority Critical
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Priority to PCT/US2003/024209 priority patent/WO2004010957A2/en
Publication of AT516818T publication Critical patent/AT516818T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
AT03772186T 2002-07-31 2003-07-31 Auristatin conjugates and their use for the treatment of cancer, autoimmunk range, or infectious disease AT516818T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US40040302P true 2002-07-31 2002-07-31
PCT/US2003/024209 WO2004010957A2 (en) 2002-07-31 2003-07-31 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease

Publications (1)

Publication Number Publication Date
AT516818T true AT516818T (en) 2011-08-15

Family

ID=31188683

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03772186T AT516818T (en) 2002-07-31 2003-07-31 Auristatin conjugates and their use for the treatment of cancer, autoimmunk range, or infectious disease

Country Status (15)

Country Link
US (5) US7659241B2 (en)
EP (3) EP1545613B9 (en)
JP (1) JP4741838B2 (en)
AT (1) AT516818T (en)
AU (2) AU2003263964C1 (en)
CA (2) CA2494105C (en)
CY (1) CY1111894T1 (en)
DK (2) DK1545613T3 (en)
ES (3) ES2369542T3 (en)
HK (1) HK1157180A1 (en)
HU (2) HUE027549T2 (en)
LU (1) LU92133I9 (en)
PT (2) PT1545613E (en)
SI (2) SI2357006T1 (en)
WO (1) WO2004010957A2 (en)

Families Citing this family (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
JP4414142B2 (en) 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Specific binding proteins and uses thereof
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
CA2494105C (en) 2002-07-31 2013-04-02 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20040081653A1 (en) * 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ES2347959T3 (en) * 2003-02-20 2010-11-26 Seattle Genetics, Inc. Anti-cd70-farmaco antibodies conjugates and their use for cancer treatment.
EP1628992A4 (en) 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic Methods of modulating metastasis and skeletal related events resulting from metastases
CN103394083B (en) 2003-11-06 2017-07-18 西雅图基因公司 Monomethyl valine compound that can be with ligand coupling
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
WO2005082023A2 (en) * 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2558399C (en) * 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1799262A4 (en) * 2004-10-15 2009-10-21 Seattle Genetics Inc Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
ES2715776T3 (en) * 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatins that have an aminobenzoic acid unit at the N-terminus
EP1827492B1 (en) 2004-11-30 2010-08-11 Curagen Corporation Antibodies directed to gpnmb and uses thereof
US8165517B2 (en) 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
CN101287498B (en) * 2005-06-20 2013-03-27 Psma开发有限公司 Psma antibody - drug conjugates
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
BRPI0612407A2 (en) * 2005-07-08 2010-11-03 Elan Pharm Inc preparation of polymeric conjugates of therapeutic compounds, agricultural compounds and food additives
US8039273B2 (en) * 2005-07-18 2011-10-18 Seattle Genetics, Inc. β-glucuronide-linker drug conjugates
ES2527961T3 (en) * 2005-09-26 2015-02-02 Medarex, L.L.C. human monoclonal antibodies to CD70
AR059900A1 (en) 2006-03-17 2008-05-07 Genentech Inc Anti-TAT226 antibodies and immunoconjugates
AU2007253717A1 (en) * 2006-05-22 2007-11-29 Elan Pharmaceuticals, Inc. Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds
ES2444010T3 (en) 2006-05-30 2014-02-21 Genentech, Inc. Antibodies and immunoconjugates and uses thereof
WO2008025020A2 (en) * 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
EP2845866B1 (en) 2006-10-27 2017-05-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
SI2099823T1 (en) 2006-12-01 2015-01-30 Seattle Genetics, Inc. Variant target binding agents and uses thereof
NZ578354A (en) * 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
JP5276017B2 (en) 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Use of anti-EGFR antibodies in the treatment of EGFR mutant mediated diseases
MX2009008430A (en) 2007-02-09 2009-10-28 Genentech Inc Anti-robo4 antibodies and uses therefor.
CA2680854C (en) * 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US8114967B2 (en) 2007-03-27 2012-02-14 Sea Lane Biotechnologies Llc Constructs and libraries comprising antibody surrogate light chain sequences
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
CL2008001334A1 (en) 2007-05-08 2008-09-22 Genentech Inc Anti-MUC16 antibody designed with cysteine; conjugate comprising the same; Method of production; pharmaceutical formulation comprising it; and its use to treat cancer.
MX2010008437A (en) 2008-01-31 2010-11-25 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use.
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
ES2609915T3 (en) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 addressed to the EGF receptor and derivatives and uses thereof
WO2009026177A1 (en) * 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CA2971794A1 (en) 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
MX2010003977A (en) 2007-10-12 2010-04-30 Seattle Genetics Inc Combination therapy with antibody-drug conjugates.
AU2008311815B2 (en) 2007-10-19 2014-02-06 Seattle Genetics, Inc. CD19 binding agents and uses thereof
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
EP2078492A1 (en) * 2008-01-11 2009-07-15 Boehringer Mannheim Gmbh Tape cassette for a medical hand device and blood sugar measuring system
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
NO2842575T3 (en) * 2008-03-18 2018-02-24
JP5752592B2 (en) 2008-04-11 2015-07-22 シアトル ジェネティックス, インコーポレイテッド Detection and treatment of pancreatic cancer, ovarian cancer, and other cancers
MX2010011807A (en) 2008-04-30 2011-03-04 Immunogen Inc Cross-linkers and their uses.
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
WO2010027513A2 (en) 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CN102317319B (en) 2008-12-09 2016-06-29 根马布股份公司 People's antibody for tissue factor
CA3051090A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
BRPI1013645A2 (en) * 2009-03-06 2019-07-02 Agensys Inc antibody drug conjugate and its pharmaceutical composition
WO2010126551A1 (en) 2009-04-30 2010-11-04 Immunogen, Inc. Potent conjugates and hydrophilic linkers
WO2010132604A2 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
RU2595424C2 (en) 2009-06-03 2016-08-27 Иммьюноджен, Инк. Methods of conjugation
RU2012101999A (en) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи Fc RECOMBINED SITES FOR SITE-SPECIFIC CONJUGATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc Dr5 ligand drug conjugates
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
BR112012007523A2 (en) 2009-10-23 2017-06-20 Amgen British Columbia anti-gcc antibody molecules and related compositions and methods
MX2012006072A (en) 2009-11-30 2012-07-23 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ).
DK2510011T3 (en) 2009-12-09 2014-12-01 Inst Nat Santé Et De La Rech Médicale Monoclonal antibodies binding b7h6 and applications thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
KR101510413B1 (en) 2010-02-08 2015-04-08 어젠시스 인코포레이티드 Antibody drug conjugates (adc) that bind to 161p2f10b proteins
RU2595389C2 (en) 2010-02-23 2016-08-27 Дженентек, Инк. Compositions and methods for diagnosing and treating cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2542576B1 (en) * 2010-03-02 2016-04-20 Seattle Genetics, Inc. Methods for screening antibodies
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
LT2558538T (en) 2010-04-15 2019-09-25 Kodiak Sciences Inc. High molecular weight zwitterion-containing polymers
NZ602933A (en) 2010-04-15 2014-09-26 Seattle Genetics Inc Pyrrolobenzodiazepines used to treat proliferative diseases
CN103796678B (en) 2011-04-20 2018-02-27 健玛保 For HER2 bispecific antibody
KR20130098165A (en) 2010-06-03 2013-09-04 제넨테크, 인크. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
SG10201600791TA (en) 2010-06-08 2016-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
JP5791707B2 (en) 2010-06-10 2015-10-07 シアトル ジェネティックス, インコーポレイテッド Novel auristatin derivatives and uses thereof
US9168314B2 (en) 2010-06-15 2015-10-27 Genmab A/S Human antibody drug conjugates against tissue factor
CN103052649B (en) 2010-07-29 2015-12-16 Xencor公司 Antibodies having a modified isoelectric point
JP5933562B2 (en) 2010-09-29 2016-06-15 シアトル ジェネティックス, インコーポレイテッド N-carboxyalkyl-auristatin and uses thereof
DK2621526T3 (en) 2010-09-29 2018-08-06 Agensys Inc Antibody-pharmaceutical conjugates (adc) binding to 191p4d12 proteins
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9272052B2 (en) 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
ES2620264T3 (en) 2010-12-06 2017-06-28 Seattle Genetics Inc Humanized antibodies against LIV-1 and their use to treat cancer
TWI589589B (en) 2010-12-20 2017-07-01 建南德克公司 Anti-mesothelin antibodies and immunoconjugates
AR084747A1 (en) 2010-12-30 2013-06-05 Takeda Pharmaceutical Anti-CD38 antibodies
KR20140016262A (en) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
CN103764667B (en) 2011-03-16 2017-06-20 西雅图基因公司 N carboxyalkyl ear Statins and its application
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
JP6161592B2 (en) 2011-03-30 2017-07-12 アリゾナ・ボード・オブ・リージェンツ,フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステート・ユニバーシティArizona Board Of Regents, For And On Behalf Of Arizona State University Auristatin tyramine phosphate and auristatin aminoquinoline derivatives and prodrugs thereof
CN103826661B (en) 2011-04-21 2019-03-05 西雅图基因公司 New bonding agent-drug conjugate (ADC) and application thereof
ES2567276T3 (en) 2011-05-12 2016-04-21 Genentech, Inc. LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
ES2643694T3 (en) 2011-05-19 2017-11-23 Inserm (Institut National De La Santé Et De La Recherche Medicale) Human anti-HER3 antibodies and their uses
WO2012159027A2 (en) 2011-05-19 2012-11-22 President And Fellows Of Harvard College Osw-1 analogs and conjugates, and uses thereof
NZ618261A (en) * 2011-05-27 2016-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
UA112434C2 (en) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Antigen-binding protein that specifically binds to vsma
BR112013030372A2 (en) * 2011-05-27 2016-08-30 Ambrx Inc compositions containing, methods involving, and uses of unnatural amino acid-linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2928504B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
TWI603741B (en) * 2011-06-10 2017-11-01 梅爾莎納醫療公司 Protein-polymer-drug conjugates
AU2012272930B2 (en) 2011-06-21 2015-06-11 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
WO2012175691A1 (en) 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
CN104220093A (en) 2011-07-06 2014-12-17 根马布私人有限公司 Antibody variants and uses thereof
SG10201605703TA (en) 2012-07-06 2016-09-29 Genmab B V Dimeric protein with triple mutations
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EA027971B1 (en) 2011-09-20 2017-09-29 Медимьюн Лимитед Pyrrolobenzodiazepines
ES2708699T3 (en) 2011-09-29 2019-04-10 Seattle Genetics Inc Determination of the intact mass of protein-conjugated compounds
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
JP6117801B2 (en) 2011-10-14 2017-04-19 メドイミューン・リミテッドMedImmune Limited Pyrrolobenzodiazepine
CN108164551A (en) 2011-10-14 2018-06-15 西雅图基因公司 Pyrrolobenzodiazepines Zhuo and targeting conjugate
EA028457B1 (en) 2011-10-14 2017-11-30 Медимьюн Лимитед Pyrrolobenzodiazepines
NZ623216A (en) 2011-10-14 2016-05-27 Seattle Genetics Inc Pyrrolobenzodiazepines and targeted conjugates
KR101733853B1 (en) 2011-11-17 2017-05-08 화이자 인코포레이티드 Cytotoxic peptides and antibody drug conjugates thereof
AU2012348017A1 (en) * 2011-12-05 2014-07-03 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
ES2721882T3 (en) 2011-12-23 2019-08-06 Pfizer Constant regions of genetically engineered antibody for site-specific conjugation and procedures and uses thereof
JP6052914B2 (en) 2012-01-12 2016-12-27 シナプティクス インコーポレイテッド Single-layer capacitive imaging sensor
JP2015505537A (en) 2012-01-20 2015-02-23 シー レーン バイオテクノロジーズ, エルエルシー Binding molecule conjugate
CA2864092A1 (en) 2012-02-10 2013-08-15 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc Antibodies and immunoconjugates LGR5
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
KR20150006000A (en) 2012-05-01 2015-01-15 제넨테크, 인크. Anti-pmel17 antibodies and immunoconjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP2849790B1 (en) 2012-05-15 2019-04-10 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
AR091098A1 (en) 2012-05-21 2015-01-14 Genentech Inc ANTIBODIES AGAINST LY6E and immunoconjugates and methods of use
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
CN104427995A (en) 2012-06-08 2015-03-18 比奥根艾迪克Ma公司 Chimeric clotting factors
EP2858659A4 (en) 2012-06-08 2016-09-28 Biogen Ma Inc Procoagulant compounds
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
DK2692865T3 (en) 2012-07-30 2015-02-16 Nbe Therapeutics Llc Transponeringsmedieret identification of specific binding proteins, or functional
US9464141B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
JP2015529656A (en) 2012-08-02 2015-10-08 ジェネンテック, インコーポレイテッド Anti-ETBR antibodies and immune complexes
EP2887959B1 (en) 2012-08-23 2018-12-19 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
SI2890402T1 (en) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
DK2766048T3 (en) 2012-10-12 2015-03-02 Spirogen Sarl Pyrrolobenzodiazepins and conjugates thereof
KR101995621B1 (en) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
MX362004B (en) 2012-10-12 2019-01-03 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
LT2906296T (en) 2012-10-12 2018-06-11 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
SI2906298T1 (en) 2012-10-12 2018-12-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6367204B2 (en) 2012-10-12 2018-08-01 メドイミューン・リミテッドMedImmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
SG11201502896XA (en) * 2012-10-16 2015-05-28 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
CN104755482B (en) 2012-10-30 2017-04-26 内尔维阿诺医学科学有限公司 functionalized 9-bromo-camptothecin derivatives
EP3508503A1 (en) 2012-11-01 2019-07-10 Max-Delbrück-Centrum für Molekulare Medizin Antibody against cd269 (bcma)
PT2917195T (en) 2012-11-05 2018-02-09 Pfizer Spliceostatin analogs
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
KR20150104092A (en) 2012-11-15 2015-09-14 엔도사이트, 인코포레이티드 Conjugates for treating diseases caused by psma expressing cells
ES2701076T3 (en) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093671A1 (en) 2012-12-12 2014-06-19 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
EP2934585B1 (en) 2012-12-21 2018-06-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US20150314007A1 (en) 2012-12-21 2015-11-05 Glykos Finland Oy Linker-payload molecule conjugates
CA2896690A1 (en) 2012-12-21 2014-06-26 Abgenomics International Inc. Hydrophilic self-immolative linkers and conjugates thereof
AU2013372331A1 (en) 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
AU2014232501B2 (en) 2013-03-15 2019-03-07 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US20140370013A1 (en) 2013-01-14 2014-12-18 Xencor, Inc. Novel heterodimeric proteins
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP6436965B2 (en) 2013-03-14 2018-12-12 ジェネンテック, インコーポレイテッド Anti-B7-H4 antibody and immunoconjugate
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
TR201911139T4 (en) 2013-03-15 2019-08-21 Zymeworks Inc The cytotoxic and anti-mitotic compounds and methods of using them.
AU2014228172B2 (en) 2013-03-15 2018-12-06 Abbvie Deutschland Gmbh & Co.Kg Anti-EGFR antibody drug conjugate formulations
US20140294759A1 (en) 2013-03-15 2014-10-02 Seung Chu Targeting regulatory t cells with heterodimeric proteins
JP2016519070A (en) 2013-03-15 2016-06-30 アッヴィ・インコーポレイテッド Purification of antibody-drug conjugate (ADC)
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US20160106860A1 (en) 2013-05-02 2016-04-21 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
WO2014194247A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105358574A (en) 2013-05-31 2016-02-24 基因泰克公司 Anti-wall teichoic antibodies and conjugates
RU2015156888A3 (en) 2013-06-04 2018-05-30
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014296219A1 (en) * 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9542023B2 (en) 2013-08-07 2017-01-10 Synaptics Incorporated Capacitive sensing using matrix electrodes driven by routing traces disposed in a source line layer
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
JP2016530254A (en) 2013-08-12 2016-09-29 ジェネンテック, インコーポレイテッド 1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound and methods of use and treatment
CN105848671A (en) 2013-08-28 2016-08-10 施特姆森特克斯股份有限公司 Site-specific antibody conjugation methods and compositions
EA201600252A1 (en) 2013-09-12 2017-05-31 Галозим, Инк. Modified antibodies to receptors of antiepidermal growth factor and methods for their use
RU2016109247A (en) 2013-09-17 2017-10-19 Дженентек, Инк. Ways of application of antibodies to lgr5
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3055298A1 (en) 2013-10-11 2016-08-17 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR20160067181A (en) 2013-10-11 2016-06-13 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
EA201690599A1 (en) 2013-10-11 2016-07-29 Оксфорд Биотерепьютикс Лтд. Conjugated antibodies against ly75 for cancer treatment
AU2014331667B2 (en) 2013-10-11 2019-08-22 Biomed Valley Discoveries, Inc. TEM8 antibodies and their use
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EA201690780A1 (en) * 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Pediated medicine-links for improved pharmacokinetics of ljand-medicine conjugates
NZ718812A (en) 2013-10-18 2017-08-25 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
JP2017500007A (en) 2013-10-21 2017-01-05 ジェネンテック, インコーポレイテッド Anti-Ly6E antibody and method of use
US9495046B2 (en) 2013-10-23 2016-11-15 Synaptics Incorporated Parasitic capacitance filter for single-layer capacitive imaging sensors
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
EP3066118A2 (en) 2013-11-06 2016-09-14 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
MX2016005854A (en) 2013-11-07 2017-07-28 Inserm (Institut Nat De La Santé Et De La Rech Médicale) Neuregulin allosteric anti-her3 antibody.
EP3074036B1 (en) 2013-11-25 2019-09-18 Seattle Genetics, Inc. Preparing antibodies from cho cell cultures for conjugation
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EA201691214A1 (en) 2013-12-13 2016-12-30 Дженентек, Инк. Antibodies to cd33 and immunoconjugates
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015108998A2 (en) 2014-01-15 2015-07-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cartilage targeting agents and their use
MX2016009515A (en) 2014-01-24 2016-10-26 Genentech Inc Methods of using anti-steap1 antibodies and immunoconjugates.
WO2015113476A1 (en) 2014-01-29 2015-08-06 上海恒瑞医药有限公司 Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
FR3017298B1 (en) 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugates and pro-drugs for the treatment of cancer and inflammatory diseases
JP2017506262A (en) 2014-02-11 2017-03-02 シアトル ジェネティクス,インコーポレイティド Selective reduction of proteins
CR20160437A (en) 2014-02-21 2017-02-20 Abbvie Stemcentrx Llc Antibody Conjugates similar to drosophila anti-delta 3 (anti-DLL3) and medicaments for use in treating melanoma
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
AU2014384434B2 (en) 2014-02-28 2016-11-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
CA2943621A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9260478B2 (en) 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
FR3020063A1 (en) 2014-04-16 2015-10-23 Gamamabs Pharma Anti-her4 human antibody
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
CA2952026A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
US20170189549A1 (en) 2014-06-13 2017-07-06 Glykos Finland Oy Payload-Polymer-Protein Conjugates
EP3157960A4 (en) 2014-06-20 2018-01-24 BioAlliance C.V. Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
WO2015197919A1 (en) 2014-06-25 2015-12-30 Glykos Finland Oy Antibody drug conjugates binding to high-mannose n-glycan
AU2015282627A1 (en) 2014-06-30 2017-02-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
EP3169706A1 (en) 2014-07-11 2017-05-24 Genmab A/S Antibodies binding axl
CA2991805A1 (en) 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP2017534256A (en) 2014-09-12 2017-11-24 ジェネンテック, インコーポレイテッド ANTI-CLL-1 antibody and immune complex
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AU2015318556A1 (en) 2014-09-17 2017-04-06 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
AU2015339012A1 (en) 2014-10-31 2017-06-01 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
US20170312290A1 (en) 2014-11-05 2017-11-02 Nerviano Medical Sciences S.R.L. Functionalized morpholinyl anthracycline derivatives
RU2017120688A3 (en) 2014-11-19 2019-07-17
CN104609464B (en) * 2014-11-21 2017-01-04 中国科学院电工研究所 A kind of preparation method of PbS nanometer sheet
TN2017000223A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3226911A1 (en) 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
RU2017118792A3 (en) 2014-12-03 2019-06-14
CN107249643A (en) 2014-12-09 2017-10-13 艾伯维公司 The antibody drug conjugate of BCL XL inhibitor with cell permeability
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
BR112017012351A2 (en) 2014-12-09 2018-02-27 Abbvie Inc bcl x1 inhibitor compounds that have low cell permeability and drug-antibody conjugates that include the same
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
US20160196803A1 (en) 2015-01-05 2016-07-07 Synaptics Incorporated Modulating a reference voltage to perform capacitive sensing
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
BR112017014599A2 (en) 2015-01-14 2018-01-16 Squibb Bristol Myers Co benzodiazepine dimers, conjugates thereof, and methods of preparation and use
EP3245207B1 (en) 2015-01-14 2019-08-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2016123412A1 (en) * 2015-01-28 2016-08-04 Sorrento Therapeutics, Inc. Antibody drug conjugates
AU2016215604A1 (en) 2015-02-02 2017-06-29 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
AU2016226083A1 (en) 2015-03-05 2017-10-12 Sirenas Llc Cyclic peptide analogs and conjugates thereof
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
US20180106779A1 (en) 2015-05-12 2018-04-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
US20180134788A1 (en) 2015-05-26 2018-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
KR20180019592A (en) 2015-06-23 2018-02-26 브리스톨-마이어스 스큅 컴퍼니 Macrocycline benzodiazepine dimer, conjugate thereof, preparation method and uses
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
AU2016335750A1 (en) 2015-10-07 2018-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
CN108779162A (en) 2015-10-09 2018-11-09 美天施生物科技有限公司 Chimeric antigen receptor and application method
WO2017064034A1 (en) 2015-10-12 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
JP2018537416A (en) 2015-10-16 2018-12-20 ジェネンテック, インコーポレイテッド Constrained disulfide drug conjugate
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
US20170119902A1 (en) * 2015-11-03 2017-05-04 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
US10035856B2 (en) 2015-11-19 2018-07-31 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
EP3383909A1 (en) 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
EP3383910A1 (en) 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400A (en) 2015-12-31 2017-07-07 辛纳普蒂克斯公司 Single layer sensor pattern and method for sensing
JP2019503686A (en) 2016-01-08 2019-02-14 バイオアライアンス セー.フェー. Tetravalent anti-PSGL-1 antibody and use thereof
MX2018008300A (en) 2016-01-13 2018-09-21 Genmab As Formulation for antibody and drug conjugate thereof.
MX2018008926A (en) 2016-01-20 2019-01-10 Scripps Research Inst Ror1 antibody compositions and related methods.
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
CN109069664A (en) 2016-01-27 2018-12-21 苏特罗生物制药公司 Anti- CD74 antibody coupling matter, the application method of the composition comprising anti-CD74 antibody coupling matter and anti-CD74 antibody coupling matter
WO2017133745A1 (en) 2016-02-05 2017-08-10 Rigshospitalet ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
WO2017147597A1 (en) 2016-02-27 2017-08-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide vaccines comprising self-assembling polymer nanoparticles
US20170252458A1 (en) * 2016-03-02 2017-09-07 Eisai Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
KR20180118173A (en) 2016-03-04 2018-10-30 제넨테크, 인크. Method for producing antibody-rifamycin conjugate
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017162678A1 (en) 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
KR20190008339A (en) 2016-05-17 2019-01-23 애브비 바이오테라퓨틱스 인크. Anti-cMet antibody drug conjugates and methods of using them
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3468596A2 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN109562168A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-CD 98 antibody and antibody drug conjugates
BR112018075626A2 (en) 2016-06-08 2019-03-19 Abbvie Inc anti-B7-H3 antibody drug conjugates and antibodies
CA3027033A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
WO2017214282A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
CA3027181A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
CN109641962A (en) 2016-06-08 2019-04-16 艾伯维公司 Anti- B7-H3 antibody and antibody drug conjugates
BR112018075639A2 (en) 2016-06-08 2019-04-09 Abbvie Inc conjugated anti-EGFR antibody drug
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
CN106674347A (en) * 2016-08-16 2017-05-17 滨州医学院 Novel ear chalone antibody
WO2018045325A1 (en) 2016-09-02 2018-03-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
US20190211060A1 (en) 2016-09-02 2019-07-11 Sirenas Llc Cyclic peptide analogs and conjugates thereof
EP3529269A2 (en) 2016-10-19 2019-08-28 Invenra, Inc. Antibody constructs
US20190256595A1 (en) 2016-10-25 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
CN109890417A (en) 2016-10-28 2019-06-14 东丽株式会社 The treatment of cancer and/or prophylactic compositions
WO2018083126A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
CA3042889A1 (en) 2016-11-14 2018-05-17 Millennium Pharmaceuticals, Inc. Non-adult human dosing of anti-cd30 antibody-drug conjugates
US20180154018A1 (en) 2016-11-23 2018-06-07 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN106854245A (en) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 Protein monoclonal antibody of AntiCD3 McAb 0 and application thereof
WO2018129524A1 (en) 2017-01-09 2018-07-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CA3053906A1 (en) 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
WO2018175988A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
WO2018187791A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
TW201904613A (en) 2017-04-27 2019-02-01 美商西雅圖遺傳學公司 Quaternized niacinamide gland dinucleotide salvage synthesis inhibitor conjugates
WO2018199337A1 (en) 2017-04-28 2018-11-01 味の素株式会社 Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
WO2018210824A1 (en) 2017-05-16 2018-11-22 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
WO2018233571A1 (en) * 2017-06-19 2018-12-27 四川百利药业有限责任公司 Antibody-drug conjugate having acidic self-stabilization junction
WO2018234843A1 (en) 2017-06-22 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
WO2018237262A1 (en) 2017-06-22 2018-12-27 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2018237335A1 (en) 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
WO2019055931A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. Anti- folate receptor alpha antibody conjugates and their uses
TW201922281A (en) 2017-10-11 2019-06-16 美商西雅圖遺傳學公司 Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
WO2019074124A1 (en) 2017-10-12 2019-04-18 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
CN107759699A (en) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 Target transgenic T cells of CD30 antigens and preparation method and application
WO2019089870A1 (en) 2017-11-01 2019-05-09 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
WO2019104084A1 (en) * 2017-11-22 2019-05-31 Seattle Genetics, Inc. Acid-mediated assay for analyzing ligand-drug conjugates
WO2019102435A1 (en) 2017-11-27 2019-05-31 Euro-Celtique S.A. Humanized antibodies targeting human tissue factor
WO2019108733A2 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
WO2019109007A1 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Humanized anti-liv1 antibodies for the treatment of breast cancer
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
WO2019164987A1 (en) * 2018-02-20 2019-08-29 Seattle Genetics, Inc. Hydrophobic auristatin f compounds and conjugates thereof
WO2019170710A2 (en) 2018-03-07 2019-09-12 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
US20190290775A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
WO2019212357A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3445518A (en) * 1966-05-06 1969-05-20 Warner Lambert Pharmaceutical P-acylphenylethylamines
US4414205A (en) * 1981-08-28 1983-11-08 University Patents, Inc. Cell growth inhibitory substances
CA1213229A (en) 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPH0373280B2 (en) 1984-08-15 1991-11-21 Shingijutsu Kaihatsu Jigyodan
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloperoxidase - Ma cell line
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp Modular unit of antibody genes, antibodies prepared therefrom and use.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01202700A (en) 1988-02-09 1989-08-15 Mitsubishi Electric Corp X-ray mirror and its manufacturing method
IL89220A (en) * 1988-02-11 1994-02-27 Squibb Bristol Myers Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
ES2083972T3 (en) 1988-08-12 1996-05-01 Astra Ab Arylalkyl-amines and amides with anticonvulsant and neuroprotective properties.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5767236A (en) * 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
DE69127627D1 (en) 1990-08-29 1997-10-16 Genpharm Int Production and Nützung nonhuman transgentiere heterologous antibody production
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE69233254D1 (en) * 1991-06-14 2004-01-08 Genentech Inc Humanized antibodies heregulin
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR0185440B1 (en) * 1991-08-09 1999-04-01 야마구찌 다까시 Tetrapeptide derivative having antitumor activity
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69308573T2 (en) 1992-08-17 1997-08-07 Genentech Inc bispecific immunoadhesine
DE69327247T2 (en) 1992-09-09 2000-05-18 Nippon Kayaku Kk Physiologically active substance NK175203, processes for their preparation and pharmaceutical use
US6034065A (en) * 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6569834B1 (en) * 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) * 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) * 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (en) 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd New tetrapeptide derivative
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2710536B1 (en) 1993-09-29 1995-12-22 Transgene Sa anticancer use of a viral vector comprising a gene modulator of the immune and / or inflammatory.
AU689131B2 (en) * 1993-10-01 1998-03-26 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) * 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
CA2210620C (en) * 1995-01-18 2004-06-22 Boehringer Mannheim Gmbh Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
CN1113066C (en) * 1995-04-21 2003-07-02 帝国脏器制药株式会社 Peptide derivatives
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JPH0977791A (en) 1995-09-08 1997-03-25 Nippon Kayaku Co Ltd Peptide derivative and its use
SE9503380D0 (en) * 1995-09-29 1995-09-29 Pharmacia Ab protein derivatives
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
WO1998013059A1 (en) 1996-09-27 1998-04-02 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
DE69832158T2 (en) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolation and structural explanation of cryostatic linears and cyclo depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6162930A (en) * 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO1999035164A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides
JP2000009062A (en) 1998-06-18 2000-01-11 Sanden Corp Scroll type compressor
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US20050238650A1 (en) * 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
WO2000047228A1 (en) * 1999-02-12 2000-08-17 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
DE60011612T2 (en) * 1999-04-28 2005-07-07 Board of Regents, The University of Texas System, Austin Compositions and methods of cancer treatment by the selective inhibition of VEGF
HU0202238A3 (en) * 1999-07-12 2004-05-28 Idec Pharmaceuticals Inc San D Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ES2637801T3 (en) * 2000-04-11 2017-10-17 Genentech, Inc. multivalent antibodies and uses thereof
US7090843B1 (en) * 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en) * 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) * 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
AU2002363939A1 (en) * 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
CA2476182A1 (en) 2002-03-01 2003-09-12 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
AU2003252830B2 (en) * 2002-03-08 2008-10-09 Abbvie Biotherapeutics Inc. Antibodies against cancer antigen TMEFF2 and uses thereof
EP1576169B1 (en) * 2002-03-19 2016-08-10 Celldex Therapeutics, Inc. Therapeutic polypeptides and methods of use
CA2494104A1 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
CA2494105C (en) 2002-07-31 2013-04-02 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003259163B2 (en) * 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
JP4898120B2 (en) * 2002-12-20 2012-03-14 アボット バイオセラピューティクス コーポレイション Antibodies against GPR64 and methods of use thereof
ES2347959T3 (en) * 2003-02-20 2010-11-26 Seattle Genetics, Inc. Anti-cd70-farmaco antibodies conjugates and their use for cancer treatment.
JP2007525434A (en) * 2003-03-19 2007-09-06 アブジェニックス インコーポレイテッド Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof.
CN103394083B (en) * 2003-11-06 2017-07-18 西雅图基因公司 Monomethyl valine compound that can be with ligand coupling
WO2005082023A2 (en) * 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7399469B2 (en) * 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
US7442332B2 (en) * 2004-05-04 2008-10-28 Clopay Plastic Products Company, Inc. Method and apparatus for uniformly stretching thermoplastic film and products produced thereby
CA2567914A1 (en) * 2004-06-02 2005-12-15 F. Hoffmann-La Roche Ag Synthesis of amino-alkoxy-heptanoic alkyl ester
ES2579805T3 (en) * 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
BRPI0516577A (en) * 2004-10-05 2008-09-16 Genentech Inc therapeutic agents with reduced toxicity
EP1827492B1 (en) 2004-11-30 2010-08-11 Curagen Corporation Antibodies directed to gpnmb and uses thereof
EP1828117A1 (en) * 2004-12-13 2007-09-05 F. Hoffmann-Roche AG Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
WO2006083936A2 (en) 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same
JP2008535823A (en) * 2005-03-25 2008-09-04 アブジェニックス インコーポレイテッド Antibodies against major antigens of tenascin
CN101287498B (en) * 2005-06-20 2013-03-27 Psma开发有限公司 Psma antibody - drug conjugates
US20090304721A1 (en) 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
EP2548583A3 (en) 2005-11-10 2013-02-27 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US20100040637A1 (en) 2005-11-23 2010-02-18 Karen Van Orden Methods and Composition for Treating Diseases Targeting Prominin-1 (CD133)
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Mn antibodies and methods for their use
AR059900A1 (en) 2006-03-17 2008-05-07 Genentech Inc Anti-TAT226 antibodies and immunoconjugates

Also Published As

Publication number Publication date
PT2357006E (en) 2016-01-22
US20080213289A1 (en) 2008-09-04
JP2006500333A (en) 2006-01-05
US20110064753A1 (en) 2011-03-17
ES2544527T3 (en) 2015-09-01
EP2357006A3 (en) 2011-10-19
US7851437B2 (en) 2010-12-14
DK1545613T3 (en) 2011-11-14
WO2004010957A3 (en) 2004-06-10
CY1111894T1 (en) 2015-11-04
EP2353611A2 (en) 2011-08-10
EP2357006B1 (en) 2015-09-16
SI2357006T1 (en) 2016-01-29
PT1545613E (en) 2011-09-27
CA2494105A1 (en) 2004-02-05
JP4741838B2 (en) 2011-08-10
AU2010201459B2 (en) 2012-12-06
US20100062008A1 (en) 2010-03-11
US20090324621A1 (en) 2009-12-31
WO2004010957B1 (en) 2004-08-19
EP1545613A4 (en) 2008-10-15
EP2353611A3 (en) 2011-10-19
EP2353611B1 (en) 2015-05-13
HUS1300002I1 (en) 2016-08-29
US7829531B2 (en) 2010-11-09
AU2003263964A1 (en) 2004-02-16
WO2004010957A2 (en) 2004-02-05
AU2010201459A1 (en) 2010-05-06
US20060074008A1 (en) 2006-04-06
AU2003263964C1 (en) 2010-08-19
US7659241B2 (en) 2010-02-09
AU2003263964B2 (en) 2010-01-14
ES2369542T3 (en) 2011-12-01
US8906376B2 (en) 2014-12-09
LU92133I9 (en) 2019-01-04
CA2494105C (en) 2013-04-02
EP1545613A2 (en) 2005-06-29
CA2802205A1 (en) 2004-02-05
EP1545613B9 (en) 2012-01-25
ES2556641T3 (en) 2016-01-19
CA2802205C (en) 2016-01-19
EP2357006A2 (en) 2011-08-17
HK1157180A1 (en) 2016-04-01
DK2357006T3 (en) 2015-12-21
EP1545613B1 (en) 2011-07-20
HUE027549T2 (en) 2016-10-28
LU92133I2 (en) 2013-03-18
SI1545613T1 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
DK2105158T3 (en) The catheter device
DE60226912D1 (en) Quinoline and chianzoline derivatives for the treatment of tumors
DE60223502D1 (en) Medical sling
DE60219702D1 (en) disposable diaper
DK1897569T3 (en) Vacuum-supported tissue treatment system
DK2336147T3 (en) Beta-immunogen-peptide carrier conjugates and procedures for producing thereof
DE60334364D1 (en) Treatment procedure using anti-cd22 antibodies
DE60023128D1 (en) Pyrazolecarboxamide for the treatment of fatibility and other diseases
DE60236858D1 (en) Blood
DK1644363T3 (en) Triheterocyclic compounds, compositions and methods for the treatment of cancer or viral diseases
DE60207692D1 (en) Röntgenopakes intraluminal medical device
DK1349870T3 (en) Compositions for the therapy and diagnosis of ovarian cancer
DE60210059D1 (en) Catheter
DE60216139D1 (en) Arylarin compounds in combination with other cytostatic or cytotoxic active substances for the treatment of human cancer disorders
DK1679319T3 (en) Procedures for the Prevention and Treatment of Alzheimer's Disease (AD)
DE50202355D1 (en) Medical instrument
DK1265630T3 (en) Use of insulin for the treatment of cartilage disease
DE50206576D1 (en) Medical implant for the human or animal body
DE60204722D1 (en) Quinazoline derivatives for the treatment of t-cell-mediated diseases
DE60205514D1 (en) disposable diaper
DE60237969D1 (en) Human antibodies against timp-1
DK1438481T3 (en) treatment Preparation
DK1419150T3 (en) 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-one derivatives, their preparation and their therapeutic use
DE60222804D1 (en) 3- (2,4) dihydroxyphenyl-4-phenylpyrazole and their medical use
DK1287799T3 (en) disposable diaper

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1545613

Country of ref document: EP